CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0675

Phenethyl bromide (2-bromoethylbenzene) CAS 103-63-9

Filed under Raw Materials. The bureau holds 110 laboratory returns for this compound from 33 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

33 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760 A 5 10.0 9.9 10.0 24 May 2026 24 May 2026
Hubei JianxiangCASE #VI-2026-0048 A 4 10.0 9.9 10.0 18 Mar 2026 25 Jun 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 4 10.0 9.9 10.0 18 Mar 2026 4 Jul 2026
GenScript PeptidesCASE #VI-2026-0860 A 4 10.0 9.9 10.0 24 Apr 2026 9 Aug 2026
PolyPeptide GroupCASE #VI-2026-0143 A 4 10.0 9.9 10.0 24 Jan 2026 12 Jul 2026
SinoPepCASE #VI-2026-0387 A 4 10.0 9.9 10.0 6 Apr 2026 16 Jul 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 3 10.0 9.9 10.0 4 Jan 2026 16 Apr 2026
AsymchemCASE #VI-2026-0091 A 3 10.0 9.9 10.0 10 May 2026 20 Jul 2026
AmbioPharmCASE #VI-2026-0177 A 3 10.0 9.9 10.0 7 Dec 2025 21 Mar 2026
BachemCASE #VI-2026-0314 A 2 10.0 10.0 10.0 20 Feb 2026 26 Jun 2026
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 5 9.9 9.9 10.0 14 Nov 2025 16 Apr 2026
WuXi TIDESCASE #VI-2026-0335 A 5 9.9 9.9 10.0 15 May 2026 6 Jul 2026
Sangon BioCASE #VI-2026-0671 A 4 9.9 9.9 10.0 23 Feb 2026 4 Jul 2026
QYAOBIOCASE #VI-2026-0861 A 4 9.9 9.9 10.0 9 Feb 2026 1 Jul 2026
JEEP PeptidesCASE #VI-2026-0457 A 4 9.9 9.9 10.0 26 Mar 2026 24 Jun 2026
Kerui PeptidesCASE #VI-2026-0626 A 4 9.9 9.9 10.0 20 Dec 2025 14 Jun 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 3 9.9 9.9 9.9 19 May 2026 15 Jul 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 3 9.9 9.9 10.0 8 Jan 2026 12 Aug 2026
Sigma-AldrichCASE #VI-2026-0829 A 3 9.9 9.9 10.0 23 Mar 2026 9 Jul 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 9.9 9.9 10.0 24 Dec 2025 28 May 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 9.9 9.9 10.0 22 Mar 2026 17 May 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 9.9 6 Mar 2026 14 Jul 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 2 9.9 9.9 10.0 27 Apr 2026 23 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 2 9.1 8.7 9.4 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 8 9.0 8.4 10.0 24 May 2026 24 May 2026
Atomik LabzCASE #VI-2026-0327 X 1 8.8 8.8 8.8 7 May 2025 7 May 2025
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 7 8.4 7.0 9.7 24 May 2026 24 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 4 7.9 6.2 8.8 24 May 2026 24 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 4 7.8 7.2 8.5 24 May 2026 24 May 2026
Champion PeptideCASE #VI-2026-0909 X 1 7.7 7.7 7.7 27 Feb 2025 27 Feb 2025
Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 X 1 5.2 5.2 5.2 20 Jun 2025 20 Jun 2025
Dragon PharmaCASE #VI-2026-0519 X 1 4.9 4.9 4.9 27 Feb 2025 27 Feb 2025
Marvel PeptideCASE #VI-2026-0507 X 1 1.8 1.8 1.8 3 Jul 2025 3 Jul 2025

Open any subject to view the batch-level evidence for Phenethyl bromide (2-bromoethylbenzene) CAS 103-63-9 alone.